Janux Therapeutics, Inc.
NASDAQ:JANXBiotechnology
-$0.25 today
- Market cap
- $630.80M
- Beta
- 2.52
- P/E (TTM)
- -7.6
- EPS (TTM)
- -$1.83
Volume 0.98M
Average 1.02M
JANX Other Income / Expenses
Net non-operating gains and losses, such as investment results, currency effects, and one-off items.
Janux Therapeutics, Inc.NASDAQ: JANX
Other Income / Expenses · Q1 FY2026 · quarter ended Mar 2026
Other income / expenses dips below year-ago levels
Q1 FY2026 other income / expenses of $9.85M fell 13.5% year over year, behind the +18.6% change in trailing-twelve-month other income / expenses. Sequentially, it fell 5.8% from the prior quarter. Over 3 fiscal years it compounded at +121.9% a year.
Context
- Other income / expenses amounted to 440.4% of revenue in FY2025, up 158.5 pp from a year earlier.
- Other income / expenses increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from -13.5% toward the trailing-twelve-month pace of +18.6%.
Sources:Income StatementText generated from reported figures; not investment advice.
Other Income / Expenses history
USD · from the income statement
- Latest · FY2025
- 44.04M USD
- Year-over-year change
- +47.5%
- 4-year CAGR
- +261.8%
| Period | Period end | Other Income / Expenses | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 44.04M | +47.5% |
| FY2024 | 2024-12-31 | 29.85M | +103.3% |
| FY2023 | 2023-12-31 | 14.69M | +264.2% |
| FY2022 | 2022-12-31 | 4.03M | +1468.9% |
| FY2021 | 2021-12-31 | 257K | — |
Other Income / Expenses vs competitors
How JANX compares with its peers on the latest reported figures
- Peers report in different currencies, so other income / expenses is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +18.6% is the 3rd highest of 10, against a peer median of -19.9%.
- Other income / expenses amounts to 196.7% of revenue for JANX, versus a peer median of 11.6%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $42.51M USD | +18.6% | +121.9% | 196.7% | |
| LTM Sep 2026 | $25.39M USD | -19.9% | +114.2% | 22670.5% | |
| LTM Mar 2026 | $19.31M USD | -36.3% | +48.3% | — | |
| LTM Sep 2026 | $18.04M USD | +57.2% | +600.5% | — | |
| LTM Mar 2026 | $7M USD | +6.0% | +37.7% | — | |
| LTM Mar 2026 | $5.75M USD | -2.2% | +37.4% | 16.2% | |
| LTM Sep 2026 | -$1.9M USD | +94.1% | — | 0.1% | |
| LTM Mar 2026 | -€2.64M EUR | -106.2% | — | 7.1% | |
| LTM Mar 2026 | -$7.37M USD | -116.5% | — | 4.7% | |
| LTM Mar 2026 | -$38.64M USD | -613.7% | — | 38.8% | |
VRXAVeraxa Biotech Holding AG | — | — | — | — | — |
| Peer median (excluding JANX) | — | -19.9% | +48.3% | 11.6% | |
Competitors are the stored peer set for JANX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 3.64M | 8.61M | 8.08M | 10.59M | 10M |
| Cost of Revenue | 26.24M | 841K | 1.96M | 2.06M | 2.03M |
| Gross Profit | (22.6M) | 7.77M | 6.13M | 8.53M | 7.97M |
| Gross Margin | -621.4% | 90.2% | 75.8% | 80.5% | 79.7% |
| Research & Development | 26.24M | 53.44M | 54.92M | 68.39M | 125.9M |
| Selling, General & Admin | 10.33M | 22.26M | 26.14M | 41.05M | 41.77M |
| Operating Expenses | 10.33M | 74.86M | 79.11M | 107.38M | 165.64M |
| Depreciation & Amortization | 113K | 841K | 1.96M | 2.06M | 2.03M |
| EBITDA | (32.56M) | (62.22M) | (56.34M) | (66.93M) | (111.6M) |
| EBITDA Margin | -895.2% | -722.5% | -697.0% | -632.2% | -1116.0% |
| Operating Income | (32.93M) | (67.09M) | (72.98M) | (98.85M) | (157.67M) |
| Operating Margin | -905.4% | -779.0% | -902.9% | -933.6% | -1576.7% |
| Interest Income | 257K | 4.03M | 14.69M | 29.85M | 44.04M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 257K | 4.03M | 14.69M | 29.85M | 44.04M |
| Income Before Tax | (32.67M) | (63.06M) | (58.29M) | (68.99M) | (113.63M) |
| Pre-Tax Margin | -898.3% | -732.2% | -721.2% | -651.6% | -1136.3% |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (32.67M) | (63.06M) | (58.29M) | (68.99M) | (113.63M) |
| Net Margin | -898.3% | -732.2% | -721.2% | -651.6% | -1136.3% |
| EPS (Basic) | (0.79) | (1.52) | (1.32) | (1.28) | (1.83) |
| EPS (Diluted) | (0.79) | (1.52) | (1.32) | (1.28) | (1.83) |
| Weighted Avg Shares | 41.24M | 41.47M | 44.02M | 53.75M | 61.97M |
| Weighted Avg Shares (Diluted) | 41.24M | 41.47M | 44.02M | 53.75M | 61.97M |
Janux Therapeutics, Inc.
NASDAQ:JANX
Intrinsic Alpha fair value
Locked
Current Price
$10.31
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.